GeNeuro is a French-Swiss-based clinical-stage company committed to bringing safe and effective solutions for stopping the progression of disability caused by autoimmune diseases, starting with Multiple Sclerosis and Amyotrophic Lateral Sclerosis. GeNeuro leverages the growing understanding of human endogenous retroviruses (HERVs), which are traces in the genome of viral infections that affected our ancestors, and today represent over 8% of the total human DNA. HERVs do generally not encode for proteins, but in pathological situations, HERV proteins can be expressed and found in the affected tissues. They may play a vital role in the onset and development of multiple autoimmune diseases.